The FDA has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adults with treatment-resistant depression.

Longitudinal data shows increasing or high addictive use of social media and mobile phones in adolescents significantly raises the risk of suicidal behaviors and ideation.

The FDA has approved Uzedy (risperidone) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

(HealthDay News) — Brief bouts of exercise spread throughout the day (“exercise snacks”) improve cardiorespiratory fitness in physically inactive adults, according to a review published online in the ...

The researchers found that during a median 5.72 years of follow-up, 150 incident ALS cases were recorded, yielding 7.05 cases per 100,000 person-years. (HealthDay News) — The risk for amyotrophic ...